Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 11/20 | 0.86 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.57 |
| ▸ | RNF4 | P78317 | 1/20 | 0.51 |
| ▸ | CETP | P11597 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1239623 | 0.92 | SERPINE1 (1.00) | SERPINE1NR3C1CNR2 | |
| SCHEMBL1241400 | 0.89 | SERPINE1 (0.93) | SERPINE1NR3C1CNR2 | |
| SCHEMBL1242512 | 0.89 | SERPINE1 (0.93) | SERPINE1NR3C1CNR2 | |
| SCHEMBL1242212 | 0.88 | SERPINE1 (0.67) | SERPINE1NR3C1RNF4CETPLTA4H | |
| SCHEMBL1242527 | 0.87 | SERPINE1 (0.66) | SERPINE1NR3C1EPHX2 | |
| SCHEMBL1239730 | 0.87 | SERPINE1 (0.90) | SERPINE1CNR2 | |
| SCHEMBL1241500 | 0.82 | SERPINE1 (0.82) | SERPINE1 | |
| SCHEMBL1242665 | 0.82 | SERPINE1 (0.82) | SERPINE1 | |
| SCHEMBL1239836 | 0.81 | SERPINE1 (0.81) | SERPINE1 | |
| SCHEMBL1241371 | 0.81 | SERPINE1 (0.80) | SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884234-B2 | N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20090215899-A9 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-2072498-A1 | N-PHENYLOXAMIDIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-06-24 | — | — | EP | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249175-A1 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | SERPINE1 1/4885NR3C1 3521/4885RNF4 4113/4885 |
| US-20090215899-A9 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | SERPINE1 1/4885NR3C1 3521/4885RNF4 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.